

**This communication should be viewed by:**

- Primary Care Providers
- Behavioral Health Providers
- Clinical staff

## Pharmaceutical Policy Updates Effective April 1, 2024

To view all current MVP Health Care® (MVP) Pharmaceutical policies, *Sign In* at [mvphealthcare.com](https://mvphealthcare.com) and select *Resources*, then *Medical Policies* then *Pharmaceutical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their statuses. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes**– Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective April 1, 2024 and will be available for viewing on or before March 1, 2024. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Ganaxolone	Reviewed/No Changes
Teplizumab-mzwv	Reviewed/No Changes
Teplizumab-mzwv Part B	Reviewed/No Changes
Tocilizumab	Updated
Tocilizumab Part B	Updated
Golimumab	Updated
Golimumab Part B	Updated
Abatacept	Updated
Abatacept Part B	Updated
Mail Order	Reviewed/No Changes
Prescribers Treating Self or Family Members	Reviewed/No Changes
Physician Prescription Eligibility	Reviewed/No Changes
Transgender Hormone Therapy (Commercial/Exchange/CHP)	Reviewed/No Changes
Transgender Hormone Therapy (Medicaid/HARP)	Reviewed/No Changes
Phenylketonuria Agents	Reviewed/No Changes
Acthar	Reviewed/No Changes
Certolizumab	Updated
Certolizumab Part B	Updated
Etanercept	Updated
Growth Hormone	Reviewed/No Changes
Infertility Drug Therapy (Commercial/Marketplace)	Updated

To view all communications, visit [mvphealthcare.com/FastFax](https://mvphealthcare.com/FastFax)

**Questions?** Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.



Jynarque	Updated
Male Hypogonadism	Updated
Metformin ER	Updated
Secukinumab Part B	New Policy
<b>Effective January 1, 2024</b>	
Botulinum Toxin Treatment- effective 01/01/2024	Archived
Botulinum Toxin Treatment Part B- effective 01/01/2024	Archived
<b>Effective February 1, 2024</b>	
Secukinumab	Updated
Omidubicel	New Policy
Omidubicel Part B	New Policy
Donislecel	New Policy
Donislecel Part B	New Policy
Pulmonary Hypertension (Advanced Agents) Part B	Archived
Hemophilia Gene Therapy Part B	New Policy
Vascular Endothelial Growth Factor (VEGF) Inhibitor	Updated
Vascular Endothelial Growth Factor (VEGF) Inhibitor Part B	Updated
Syfovre	Updated
Syfovre Part B	Updated

### It's Time to Recertify Your Patients!\*

The Families First Coronavirus Response Act has expired. To learn how MVP can help your patients continue their coverage, visit [mvphealthcare.com/recertification](https://mvphealthcare.com/recertification).

\*Applies to Members enrolled in Medicaid, Child Health Plus (CHP), Health and Recovery Plan (HARP), and the Essential Plan (EP).

To view all faxed messages, visit [mvphealthcare.com/FastFax](https://mvphealthcare.com/FastFax).

**Questions?** Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

